ArticleTargeted oncology2017
Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase.
Article in Targeted oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- A scoping review of imatinib-induced testicular toxicity and male fertility impairment.Frontiers in endocrinology · 2026Pooled it
- Priapism in Patients with Chronic Myeloid Leukemia (CML): A Systematic Review.Acta bio-medica : Atenei Parmensis · 2021Pooled it
- Cytotoxic Activity of Antineoplastic Agents on Fertility: A Systematic Review.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2020Pooled it
- Pooled it
- Review
- Effects of Cytotoxic Therapies on the Sperm Genome and Epigenome.Advances in experimental medicine and biology · 2026Review
- Case series - Scrotal edema associated with zanubrutinib.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026Article
- Impact of immunotherapy and small molecule cancer therapy on fertility: a narrative review of current evidence, mechanisms and future directions.BMJ oncology · 2026Review
- Article
- Imatinib decreases germ cell survival and germline stem cell proliferation in rodent testis ex vivo and in vitro.Andrology · 2025Article
- Gonadotoxicity of immunotherapy and targeted agents in patients with cancer and impact on subsequent pregnancies.Human reproduction (Oxford, England) · 2025Review
- Review
- Long-term endocrine outcomes and quality of life in paediatric and young chronic myeloid leukaemia patients on tyrosine kinase inhibitor therapy: a prospective study from India.Frontiers in oncology · 2025Article
- Management of CML and Pregnancy in Low-and Middle-income Countries.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Review
- Non-alkylating agents-induced gonadotoxicity in pre-pubertal males: Insights on the clinical and pre-clinical front.Clinical and translational science · 2024Review
- Male Fertility and Fatherhood in Chronic Myeloid Leukemia: Current Understanding and Future Perspectives.Cancers · 2024Review
- Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution.Annals of hematology · 2023Article
- The Impact of Systemic Oncological Treatments on the Fertility of Adolescents and Young Adults-A Systematic Review.Life (Basel, Switzerland) · 2023Review
- Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spaces-A Review.Pharmaceutics · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundImatinib is a first-line tyrosine kinase inhibitor for treating chronic myelogenous leukaemia (CML) and has greatly improved the prognosis of this disease. An increasing number of CML patients of reproductive age are diagnosed each year, and the impact of imatinib on fertility is a major concern. Providing useful advice to these patients regarding the choice of their therapeutic treatment is very important.
objectiveThis study examined the impact of imatinib on the fertility of male patients with CML in the chronic phase. PATIENTS AND
methodsWe performed a study of 48 adult male CML patients in the chronic phase (CML-CP), 50 healthy control subjects, and 10 male patients with infertility. Imatinib levels in semen and plasma were measured using high-performance liquid chromatography/mass spectrometry. We examined the effects of imatinib on sperm parameters and the male reproductive system using a computer-assisted sperm assay and ultrasound, respectively. We analysed sex hormone levels in the sera of CML-CP patients using an enzyme-linked immunosorbent assay.
resultsImatinib levels in semen were comparable to plasma levels in CML-CP patients. CML-CP patients treated with imatinib exhibited reduced sperm density, counts, survival rates, and activity. Ultrasound demonstrated that the shape and size of the testis and epididymis in CML-CP patients undergoing imatinib treatment were normal. However, 19 of these patients exhibited a hydrocele in their tunica vaginalis, with a large dark area of effusion (0.7-2.9 cm in width). Sex hormone levels in the sera of the CML-CP patients were normal.
conclusionsThese results suggest that imatinib crosses the blood-testis barrier and reduces sperm density, sperm count, survival rates, and activity in CML-CP patients. However, imatinib did not affect the structure of reproductive organs or sex hormone levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.